

December 3, 2020

Dear Forum Colleagues,

Regarding the COVID-19 vaccine distribution plan, I wish to share information provided by Dr. Lindsay Weaver, Chief Medical Officer, Indiana State Department of Health. On December 1, 2020, Dr. Weaver issued a <u>letter</u> detailing the distribution of the <u>Pfizer</u> and <u>Moderna</u> COVID-19 vaccine, upon their pending <u>EUA approval</u> in the United States. The Pfizer vaccine has already been <u>granted approval</u> in the UK.

Below are some important aspects of the COVID-19 vaccine distribution plan in Indiana, provided by Dr. Weaver.

- The committee formed by the Indiana State Department of Health to determine the vaccine distribution plan has agreed that healthcare personnel will be the first to receive the vaccine.
 - Due to the <u>limited supply</u> of the vaccine, only healthcare personnel who are providing care to the most vulnerable populations, have a high likelihood of coming into contact with COVID-19 positive patients and who are vital in the response to COVID-19, will be in the first phase of vaccinations.
 - If the healthcare personnel falls under the aforementioned categories, they will receive a letter with a link to register and schedule their appointment to receive the vaccine. This letter and link can come from the employer, professional licensing agency or an association.
 - \circ Initially, 50 <code>hospitals</code> in Indiana will be administering the vaccine.
 - Those who received their first dose will then need to sign up for the second dose in 21 (Pfizer) or 28 (Moderna) days.
- The vaccine will be free, but insurance will be taken and may be charged \$28 for administration fees.
- The complete Indiana vaccination <u>Phase list</u> provided by the Indiana State Department of Health is below. • Phase 1A:
 - All paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious material.

\circ Phase 1B:

 Individuals who are at particular risk of morbidity and mortality associated with COVID-19 disease based on the latest evidence-based criteria.

o Phase 2:

 Individuals who are at elevated risk of transmission of the disease because of working or living circumstances. This includes persons living in correctional facilities, group homes or shelters, and individuals whose in-person work is essential, required, and places them in settings where social distancing is not possible and transmission risk is high.

∘ Phase 3:

General public vaccination.

For more information from the Indiana State Department of Health regarding the COVID-19 vaccine, please visit this <u>link</u>.

Best, Gloria

Gloria Sachdev, BS Pharm, PharmD, FASHP President and CEO, Employers' Forum of Indiana; Clinical Associate Professor, Purdue College of Pharmacy; Assistant Professor, Indiana University School of Medicine